Imperial Innovations Group Regulatory News (IVO)

London, UK, 6 September 2016

Edison issues update on Imperial Innovations (IVO)

Imperial Innovations (IVO) has been executing on its intention to rebalance its investment portfolio away from therapeutics companies by building up activities in the non-therapeutics space, in particular ICT/digital. Ongoing investment in both established and new ICT/digital companies should see this sector grow in both importance and value. This report focuses on Featurespace, a company outside IVO's top 10 assets by value of holding at end-H116, but one that received additional investment in May ahead of important catalysts over the next year.

Imperial Innovations is a technology transfer, incubation and venture investment company. It invests in ventures from Imperial College London, Cambridge and Oxford universities and UCL. Over 90% of its portfolio value is in 20 companies, with most (c 77%) of its investments in healthcare.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: